These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9583037)

  • 21. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
    Hubble J; Schwab J; Hubert C; Abbott CC
    Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
    Wu CJ; Shen JH; Chen Y; Lian YJ
    Turk Neurosurg; 2011; 21(4):625-9. PubMed ID: 22194126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
    Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
    Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of high-dose botulinum A toxin in benign essential blepharospasm: is too high too much?
    Pang AL; O'Day J
    Clin Exp Ophthalmol; 2006 Jul; 34(5):441-4. PubMed ID: 16872340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anesthesia with EMLA cream for botulinum A toxin injection into eyelids.
    Söylev MF; Koçak N; Kuvaki B; Ozkan SB; Kir E
    Ophthalmologica; 2002; 216(5):355-8. PubMed ID: 12424403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm].
    Lasalvia CG; Pereira Lde S; da Cunha MC; Kitadai SP
    Arq Bras Oftalmol; 2006; 69(5):701-5. PubMed ID: 17187139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
    Ho RW; Fang PC; Chao TL; Chien CC; Kuo MT
    Sci Rep; 2018 May; 8(1):8367. PubMed ID: 29849166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
    Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
    Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
    Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five-Year Retrospective Review of Cases with Benign Essential Blepharospasm and Hemifacial Spasm Presenting in a Tertiary Eye Care Center in North India.
    Raj A; Arya SK; Deswal J; Bamotra RK
    Semin Ophthalmol; 2017; 32(3):371-376. PubMed ID: 27078720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time.
    Drummond GT; Hinz BJ
    Can J Ophthalmol; 2001 Dec; 36(7):398-403. PubMed ID: 11794389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Botulinum Toxins for Treating Essential Blepharospasm and Hemifacial Spasm.
    Ozzello DJ; Giacometti JN
    Int Ophthalmol Clin; 2018; 58(1):49-61. PubMed ID: 29239877
    [No Abstract]   [Full Text] [Related]  

  • 33. Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore.
    Tan AK
    Singapore Med J; 1998 Sep; 39(9):403-5. PubMed ID: 9885719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm.
    Karp BI; Alter K
    Semin Neurol; 2016 Feb; 36(1):84-91. PubMed ID: 26866500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the periocular botulinum toxin on the ocular surface and anterior chamber: a prospective study in patients with hemifacial spasm and blepharospasm.
    Romero-Caballero MD; Miralles de Imperial-Ollero JA; Sarabia-Marín E; Villegas-Pérez MP
    Int Ophthalmol; 2023 Aug; 43(8):2731-2736. PubMed ID: 37185774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
    Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
    Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm.
    Rieder CR; Schestatsky P; Socal MP; Monte TL; Fricke D; Costa J; Picon PD
    Clin Neuropharmacol; 2007; 30(1):39-42. PubMed ID: 17272968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG; Tyrrell EG; Grosset KA
    J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum toxin A injection in the treatment of hemifacial spasm.
    Chen RS; Lu CS; Tsai CH
    Acta Neurol Scand; 1996 Sep; 94(3):207-11. PubMed ID: 8899054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.